Motley Fool Asset Management LLC Buys 623 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Motley Fool Asset Management LLC lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 10.3% during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,652 shares of the biopharmaceutical company’s stock after purchasing an additional 623 shares during the quarter. Motley Fool Asset Management LLC’s holdings in Alnylam Pharmaceuticals were worth $2,169,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently made changes to their positions in ALNY. Brighton Jones LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter worth approximately $243,000. GAMMA Investing LLC raised its holdings in Alnylam Pharmaceuticals by 14.3% in the 1st quarter. GAMMA Investing LLC now owns 616 shares of the biopharmaceutical company’s stock worth $166,000 after acquiring an additional 77 shares during the last quarter. Bessemer Group Inc. raised its holdings in Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 69 shares during the last quarter. Sequoia Financial Advisors LLC raised its holdings in Alnylam Pharmaceuticals by 3.0% in the 1st quarter. Sequoia Financial Advisors LLC now owns 3,395 shares of the biopharmaceutical company’s stock worth $917,000 after acquiring an additional 99 shares during the last quarter. Finally, Sumitomo Mitsui Trust Group Inc. raised its holdings in Alnylam Pharmaceuticals by 1.7% in the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 291,476 shares of the biopharmaceutical company’s stock worth $78,704,000 after acquiring an additional 4,773 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Price Performance

Shares of ALNY opened at $475.91 on Wednesday. The firm has a market cap of $62.38 billion, a PE ratio of -192.68 and a beta of 0.36. The company has a current ratio of 2.80, a quick ratio of 2.75 and a debt-to-equity ratio of 4.10. The firm has a fifty day simple moving average of $460.05 and a two-hundred day simple moving average of $365.19. Alnylam Pharmaceuticals, Inc. has a 1-year low of $205.87 and a 1-year high of $495.55.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. The business had revenue of $773.69 million during the quarter, compared to analyst estimates of $633.54 million. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The company’s quarterly revenue was up 17.3% compared to the same quarter last year. During the same period in the previous year, the business earned ($0.13) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. On average, equities analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on ALNY shares. Bank of America boosted their price objective on shares of Alnylam Pharmaceuticals from $453.00 to $520.00 and gave the stock a “buy” rating in a report on Wednesday, September 17th. Wolfe Research upgraded shares of Alnylam Pharmaceuticals from an “underperform” rating to a “peer perform” rating in a report on Monday, August 4th. Chardan Capital boosted their price objective on shares of Alnylam Pharmaceuticals from $325.00 to $400.00 and gave the stock a “buy” rating in a report on Friday, August 1st. Weiss Ratings restated a “sell (d-)” rating on shares of Alnylam Pharmaceuticals in a report on Wednesday, October 8th. Finally, Barclays boosted their price objective on shares of Alnylam Pharmaceuticals from $329.00 to $460.00 and gave the stock an “overweight” rating in a report on Friday, August 1st. Twenty-three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $466.92.

Insider Transactions at Alnylam Pharmaceuticals

In other news, EVP Pushkal Garg sold 3,022 shares of the company’s stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $451.48, for a total value of $1,364,372.56. Following the completion of the sale, the executive vice president directly owned 20,221 shares in the company, valued at $9,129,377.08. This represents a 13.00% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Yvonne Greenstreet sold 8,924 shares of the company’s stock in a transaction on Thursday, October 2nd. The stock was sold at an average price of $452.05, for a total value of $4,034,094.20. Following the completion of the sale, the chief executive officer owned 65,409 shares of the company’s stock, valued at $29,568,138.45. This trade represents a 12.01% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 98,144 shares of company stock worth $44,160,261 over the last three months. 1.20% of the stock is currently owned by insiders.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.